Skip to content

ADRN-12/LEADS (Longitudinal Endotyping of Atopic Dermatitis Through Transcriptomic Skin Analysis)

Search Clinical Trials

Trial Objectives


Eczema (atopic dermatitis) is typically classified as mild, moderate or severe. In this trial, researchers are studying gene expression for the varying severity levels of eczema in order to guide new and improved treatments strategies and more personalized treatments. Skin samples from participants will be collected using a specialized, noninvasive dermatologic skin tape. People with and without eczema are needed for this trial.
 

Who Can Participate


Adults ages 18 and older and kids ages 6 to 17 with and without eczema.

Age: Not Specified Gender Any

Estimated Time Commitment


Not Specified

Payment & Reimbursement


Payment Provided

Travel Reimbursement Available

Trial Contact


For more information, contact:

Victoria Wessell
303.398.1077

Request More Information

Trial Location


National Jewish Main Campus, Denver, CO

Trial Sponsors


National Institutes of Health

Principal Investigators

  • Mark Boguniewicz

    Mark Boguniewicz, MD

  • Donald Y M Leung

    Donald Y M Leung, PhD, MD

Request more Information

By completing this form, you agree to learn more about this study and see if you qualify.

I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health required